Compare General Mills, Inc. (GIS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Sana Biotechnology Inc — how do they compare? General Mills, Inc. trades at $32.37 (market cap $17.43B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: General Mills, Inc. is far larger — about 20.8× Sana Biotechnology Inc's market cap, and General Mills, Inc. pays a 7.49% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Sana Biotechnology Inc for 23 Days on average.
| GIS | SANA | |
|---|---|---|
Market Cap | $17.43B | $836.71M |
Volume | 16,554,362 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $5.92 |
52-Week Low | $31.67 | $2.68 |
Typical Hold Time | 106 Days | 23 Days |
Enterprise Value | $30.61B | $749.96M |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.09, up 1.01% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces fundamental challenges with a negative net income margin of -4.89% and ROE of -10.55% for 2026, though it maintains strong operating cash flow of $2.92B in 2025. Recent leadership transition to Dana McNabb as CEO and a $3B cost-saving initiative aim to stabilize performance amid declining revenues.
The stock presents a value opportunity with a low P/E of 9.23 and a 7.6% upside to the $36 consensus target, supported by a reliable dividend. However, risks include persistent margin pressures, high debt levels at 45% of assets, and competitive headwinds in the packaged foods sector. Analyst sentiment is cautious with 61% hold ratings, reflecting uncertainty around the turnaround strategy's execution.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
